{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:09:05Z","timestamp":1795122545975,"version":"4.10.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients diagnosed with epithelial ovarian cancer (OC) have a 5-year survival rate of 49%. For early-stage disease, the 5-year survival rate is above 90%. However, advanced-stage disease accounts for most cases as patients with early stages often are asymptomatic or present with unspecific symptoms, highlighting the need for diagnostic tools for early diagnosis. Liquid biopsy is a minimal invasive blood-based approach that utilizes circulating tumor DNA (ctDNA) shed from tumor cells for real-time detection of tumor genetics and epigenetics. Increased DNA methylation of promoter regions is an early event during tumorigenesis, and the methylation can be detected in ctDNA, accentuating the promise of methylated ctDNA as a biomarker for OC diagnosis. Many studies have investigated multiple methylation biomarkers in ctDNA from plasma or serum for discriminating OC patients from patients with benign diseases of the ovaries and\/or healthy females. This systematic review summarizes and evaluates the performance of the currently investigated DNA methylation biomarkers in blood-derived ctDNA for early diagnosis of OC. PubMed\u2019s MEDLINE and Elsevier\u2019s Embase were systematically searched, and essential results such as methylation frequency of OC cases and controls, performance measures, as well as preanalytical factors were extracted. Overall, 29 studies met the inclusion criteria for this systematic review. The most common method used for methylation analysis was methylation-specific PCR, with half of the studies using plasma and the other half using serum.\n                    <jats:italic>RASSF1A<\/jats:italic>\n                    ,\n                    <jats:italic>BRCA1<\/jats:italic>\n                    , and\n                    <jats:italic>OPCML<\/jats:italic>\n                    were the most investigated gene-specific methylation biomarkers, with\n                    <jats:italic>OPCML<\/jats:italic>\n                    having the best performance measures. Generally, methylation panels performed better than single gene-specific methylation biomarkers, with one methylation panel of 103,456 distinct regions and 1,116,720 CpGs having better performance in both training and validation cohorts. However, the evidence is still limited, and the promising methylation panels, as well as gene-specific methylation biomarkers highlighted in this review, need validation in large, prospective cohorts with early-stage asymptomatic OC patients to assess the true diagnostic value in a clinical setting.\n                  <\/jats:p>","DOI":"10.1186\/s13148-023-01440-w","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T04:38:38Z","timestamp":1676349518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review"],"prefix":"10.1186","volume":"15","author":[{"given":"Simone Karlsson","family":"Terp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Pontoppidan","family":"Stoico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dybk\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge S\u00f8kilde","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"1440_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Ovarian Cancer [Internet]. 2022 [cited 2022 Oct 3]. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"1440_CR2","unstructured":"American Cancer Society. Cancer Facts & Figures [Internet]. 2022 [cited 2022 Jul 19]. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html."},{"issue":"2","key":"1440_CR3","first-page":"1","volume":"2","author":"R Bell","year":"1998","unstructured":"Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Heal Technol Assess (Rockv). 1998;2(2):1\u201384.","journal-title":"Heal Technol Assess (Rockv)."},{"issue":"22","key":"1440_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA J Am Med Assoc. 2011;305(22):2295\u2013302.","journal-title":"JAMA J Am Med Assoc"},{"issue":"4","key":"1440_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"1440_CR6","doi-asserted-by":"crossref","unstructured":"Skates SJ. Ovarian cancer screening: Development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012;22 Suppl 1: S24\u20136.","DOI":"10.1097\/IGC.0b013e318256488a"},{"issue":"1","key":"1440_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12885-018-4433-3","volume":"18","author":"B Arneth","year":"2018","unstructured":"Arneth B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer. 2018;18(1):527.","journal-title":"BMC Cancer"},{"issue":"4","key":"1440_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF03194647","volume":"47","author":"J Paluszczak","year":"2006","unstructured":"Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer\u2014the application of DNA methylation markers. J Appl Genet. 2006;47(4):365\u201375.","journal-title":"J Appl Genet"},{"issue":"4","key":"1440_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858\u201373.","journal-title":"Cancer Discov"},{"issue":"3","key":"1440_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cells9030624","volume":"9","author":"V Const\u00e2ncio","year":"2020","unstructured":"Const\u00e2ncio V, Nunes SP, Henrique R, Jer\u00f3nimo C. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 2020;9(3):624\u201355.","journal-title":"Cells."},{"issue":"6","key":"1440_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745\u201359.","journal-title":"Ann Oncol"},{"issue":"1","key":"1440_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2007.12.017","volume":"109","author":"CA Barton","year":"2008","unstructured":"Barton CA, Hacker NF, Clark SJ, O\u2019Brien PM. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 2008;109(1):129\u201339.","journal-title":"Gynecol Oncol"},{"issue":"14","key":"1440_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe MS, Etzioni R, Feng Z, Potter JD, Lou M, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054\u201361.","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"1440_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1373\/clinchem.2015.252163","volume":"62","author":"MS Pepe","year":"2016","unstructured":"Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem. 2016;62(5):737\u201342.","journal-title":"Clin Chem."},{"key":"1440_CR15","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"1440_CR16","unstructured":"Veritas Health Innovation. Covidence systematic review software [Internet]. 2022 [cited 2022 Apr 11]. https:\/\/www.covidence.org\/."},{"key":"1440_CR17","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2021. [cited 2023 Jan 5]. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"18","key":"1440_CR18","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","volume":"64","author":"II De Caceres","year":"2004","unstructured":"De Caceres II, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476\u201381.","journal-title":"Cancer Res"},{"issue":"2","key":"1440_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ijc.23957","volume":"124","author":"HY Su","year":"2009","unstructured":"Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 2009;124(2):387\u201393.","journal-title":"Int J Cancer"},{"issue":"1","key":"1440_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2353\/jmoldx.2009.080072","volume":"11","author":"A Melnikov","year":"2009","unstructured":"Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11(1):60\u20135.","journal-title":"J Mol Diagn"},{"issue":"3","key":"1440_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ygyno.2011.08.029","volume":"123","author":"AE Bondurant","year":"2011","unstructured":"Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol. 2011;123(3):581\u20137.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1440_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1371\/journal.pone.0028141","volume":"6","author":"M Campan","year":"2011","unstructured":"Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, et al. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One. 2011;6(12):141.","journal-title":"PLoS One."},{"issue":"1","key":"1440_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ygyno.2010.11.018","volume":"121","author":"N H\u00e4fner","year":"2011","unstructured":"H\u00e4fner N, Diebolder H, Jansen L, Hoppe I, D\u00fcrst M, Runnebaum IB. Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol. 2011;121(1):224\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1440_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2010.09.019","volume":"120","author":"TE Liggett","year":"2011","unstructured":"Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120(1):113\u201320.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1440_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/147323001204000231","volume":"40","author":"R Dong","year":"2012","unstructured":"Dong R, Yu J, Pu H, Zhang Z, Xu X. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J Int Med Res. 2012;40(2):681\u20136.","journal-title":"J Int Med Res"},{"issue":"2","key":"1440_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1447-0756.2012.01979.x","volume":"39","author":"YQ Wang","year":"2013","unstructured":"Wang YQ, Yan Q, Zhang JR, Di LS, Yang YX, Wan XP. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res. 2013;39(2):549\u201354.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"1440_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","volume":"130","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130(1):132\u20139.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1440_CR28","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.7314\/APJCP.2014.15.3.1171","volume":"15","author":"Y Wu","year":"2014","unstructured":"Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(3):1171\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1440_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.7754\/Clin.Lab.2013.130446","volume":"60","author":"F Zhou","year":"2014","unstructured":"Zhou F, Ma M, Tao G, Chen X, Xie W, Wang Y, Cao X. Detection of circulating methylated opioid binding protein\/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma. Clin Lab. 2014;60:759\u201365.","journal-title":"Clin Lab"},{"issue":"7","key":"1440_CR30","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.7314\/APJCP.2015.16.7.3003","volume":"16","author":"B Wang","year":"2015","unstructured":"Wang B, Yu L, Yang GZ, Luo X, Huang L. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(7):3003\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"13","key":"1440_CR31","doi-asserted-by":"publisher","first-page":"21429","DOI":"10.18632\/oncotarget.15249","volume":"8","author":"L Giannopoulou","year":"2017","unstructured":"Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017;8(13):21429\u201343.","journal-title":"Oncotarget"},{"issue":"5","key":"1440_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/ARRB\/2017\/37658","volume":"19","author":"M Swellam","year":"2017","unstructured":"Swellam M, Ramadan A, Mahmoud MS, Hashim M, Emam M. Diagnostic role of aberrant DNA promoter methylation in ovarian cancer. Annu Res Rev Biol. 2017;19(5):1\u201313.","journal-title":"Annu Res Rev Biol"},{"issue":"1","key":"1440_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3892\/ol.2017.6111","volume":"14","author":"B Wang","year":"2017","unstructured":"Wang B, Yu L, Luo X, Huang L, Li QS, Shao XS, et al. Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncol Lett. 2017;14(1):217\u201323.","journal-title":"Oncol Lett"},{"issue":"1","key":"1440_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0500-7","volume":"9","author":"M Widschwendter","year":"2017","unstructured":"Widschwendter M, Zikan M, Wahl B, Lempi\u00e4inen H, Paprotka T, Evans I, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9(1):1\u201314.","journal-title":"Genome Med"},{"issue":"2","key":"1440_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ygyno.2018.05.026","volume":"150","author":"L Giannopoulou","year":"2018","unstructured":"Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150(2):355\u201360.","journal-title":"Gynecol Oncol"},{"issue":"17","key":"1440_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20174119","volume":"20","author":"D Dvorsk\u00e1","year":"2019","unstructured":"Dvorsk\u00e1 D, Bran\u00fd D, Nagy B, Grend\u00e1r M, Poka R, Solt\u00e9sz B, et al. Aberrant methylation status of tumour suppressor genes in ovarian cancer tissue and paired plasma samples. Int J Mol Sci. 2019;20(17):1\u201319.","journal-title":"Int J Mol Sci."},{"issue":"10","key":"1440_CR37","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.31557\/APJCP.2019.20.10.3001","volume":"20","author":"S Kumar","year":"2019","unstructured":"Kumar S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant promoter hypermethylation of RASSF1a and BRCA1 in circulating cell-free tumor DNA serves as a biomarker of ovarian carcinoma. Asian Pac J Cancer Prev. 2019;20(10):3001\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1440_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-020-00939-w","volume":"12","author":"BF Miller","year":"2020","unstructured":"Miller BF, Pisanic TR, Margolin G, Petrykowska HM, Athamanolap P, Goncearenco A, et al. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers. Clin Epigenet. 2020;12(1):1\u201319.","journal-title":"Clin Epigenet"},{"issue":"6","key":"1440_CR39","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ijc.32984","volume":"147","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta S, Badarukhiya JA, Sachan M. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. Int J Cancer. 2020;147(6):1740\u201352.","journal-title":"Int J Cancer"},{"key":"1440_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cca.2021.08.020","volume":"522","author":"L Faaborg","year":"2021","unstructured":"Faaborg L, Fredslund Andersen R, Waldstr\u00f8m M, H\u00f8gdall E, H\u00f8gdall C, Adimi P, et al. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. Clin Chim Acta. 2021;522:152\u20137.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1440_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-80345-7","volume":"11","author":"BF Miller","year":"2021","unstructured":"Miller BF, Petrykowska HM, Elnitski L. Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients. Sci Rep. 2021;11(1):1\u201313.","journal-title":"Sci Rep"},{"key":"1440_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2021.719056","volume":"8","author":"A Singh","year":"2021","unstructured":"Singh A, Gupta S, Sachan M. Evaluation of the diagnostic potential of candidate hypermethylated genes in epithelial ovarian cancer in North Indian Population. Front Mol Biosci. 2021;8:1\u201320.","journal-title":"Front Mol Biosci."},{"issue":"4","key":"1440_CR43","first-page":"1","volume":"14","author":"V Tserpeli","year":"2022","unstructured":"Tserpeli V, Stergiopoulou D, Londra D, Giannopoulou L, Buderath P, Balgkouranidou I, et al. Prognostic significance of SLFN11 methylation in plasma cell-free DNA in advanced high-grade serous ovarian cancer. Cancers (Basel). 2022;14(4):1\u201315.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"1440_CR44","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2022.03.018","volume":"165","author":"LM Marinelli","year":"2022","unstructured":"Marinelli LM, Kisiel JB, Slettedahl SW, Mahoney DW, Lemens MA, Shridhar V, et al. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol. 2022;165(3):568\u201376.","journal-title":"Gynecol Oncol."},{"key":"1440_CR45","doi-asserted-by":"crossref","unstructured":"Tomeva E, Switzeny OJ, Heitzinger C, Hippe B, Haslberger AG. Comprehensive approach to distinguish patients with solid tumors from healthy controls by combining androgen receptor mutation p.H875Y with cell-free DNA methylation and circulating miRNAs. Cancers (Basel). 2022;14(462):1\u201314.","DOI":"10.3390\/cancers14020462"},{"issue":"7","key":"1440_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.heliyon.2018.e00699","volume":"4","author":"RM Trigg","year":"2018","unstructured":"Trigg RM, Martinson LJ, Parpart-Li S, Shaw JA. Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. Heliyon. 2018;4(7):e00699.","journal-title":"Heliyon"},{"issue":"4","key":"1440_CR47","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/jalm\/jfaa050","volume":"5","author":"A Samoila","year":"2020","unstructured":"Samoila A, Sosa J, Padilla J, Wutkowski M, Vanness K, Viale A, et al. Developing quality programs for cell-free Dna (cfDNA) extraction from peripheral blood. J Appl Lab Med. 2020;5(4):788\u201397.","journal-title":"J Appl Lab Med"},{"key":"1440_CR48","unstructured":"Streck. Cell-free DNA BCT\u00ae RUO & CE. 2020."},{"issue":"13","key":"1440_CR49","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1093\/nar\/29.13.e65","volume":"29","author":"C Grunau","year":"2001","unstructured":"Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001;29(13):E65\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"1440_CR50","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/nar\/gkm055","volume":"35","author":"K Munson","year":"2007","unstructured":"Munson K, Clark J, Lamparska-Kupsik K, Smith SS. Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res. 2007;35(9):2893\u2013903.","journal-title":"Nucleic Acids Res"},{"key":"1440_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-1-4939-7481-8_21","volume":"1708","author":"G Beikircher","year":"2018","unstructured":"Beikircher G, Pulverer W, Hofner M, Noehammer C, Weinhaeusel A. Multiplexed and sensitive DNA methylation testing using methylation-sensitive restriction enzymes \u201cMSRE-qPCR.\u201d Methods Mol Biol. 2018;1708:407\u201324.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"1440_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkl437","volume":"34","author":"C Gebhard","year":"2006","unstructured":"Gebhard C, Schwarzfischer L, Pham TH, Andreesen R, Mackensen A, Rehli M. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res. 2006;34(11):1\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1440_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0059068","volume":"8","author":"T De Meyer","year":"2013","unstructured":"De Meyer T, Mampaey E, Vlemmix M, Denil S, Trooskens G, Renard JP, et al. Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing. PLoS One. 2013;8(3):1\u201310.","journal-title":"PLoS One."},{"key":"1440_CR54","unstructured":"Invitrogen. MethylMinerTM Methylated DNA Enrichment Kit. For the enrichment of fragmented DNA based on the degree of methylation. Catalog no. ME10025. Manual part no. A11129. 2009."},{"issue":"22","key":"1440_CR55","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1093\/nar\/gkv795","volume":"43","author":"TR Pisanic II","year":"2015","unstructured":"Pisanic TR II, Athamanolap P, Poh W, Chen C, Hulbert A, Brock MV, et al. DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. Nucleic Acids Res. 2015;43(22):e154\u2013e154.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1440_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040838","volume":"13","author":"XM Guo","year":"2021","unstructured":"Guo XM, Miller H, Matsuo K, Roman LD, Salhia B. Circulating cell-free DNA methylation profiles in the early detection of ovarian cancer: a scoping review of the literature. Cancers (Basel). 2021;13(4):1\u201326.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1440_CR57","first-page":"386","volume":"21","author":"D Raos","year":"2021","unstructured":"Raos D, Ulamec M, Bojanac AK, Bulic-Jakus F, Jezek D, Sincic N. Epigenetically inactivated rassf1a as a tumor biomarker. Bosn J Basic Med Sci. 2021;21(4):386\u201397.","journal-title":"Bosn J Basic Med Sci"},{"issue":"3","key":"1440_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10549-013-2774-9","volume":"142","author":"L Wu","year":"2013","unstructured":"Wu L, Wang F, Xu R, Zhang S, Peng X, Feng Y, et al. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2013;142(3):619\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1440_CR59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.trecan.2019.06.002","volume":"5","author":"I Simovic","year":"2019","unstructured":"Simovic I, Casta\u00f1o-Rodr\u00edguez N, Kaakoush NO. OPCML: a promising biomarker and therapeutic avenue. Trends in Cancer. 2019;5(8):463\u20136.","journal-title":"Trends in Cancer"},{"issue":"8","key":"1440_CR60","doi-asserted-by":"publisher","first-page":"e2990","DOI":"10.1371\/journal.pone.0002990","volume":"3","author":"Y Cui","year":"2008","unstructured":"Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE. 2008;3(8):e2990.","journal-title":"PLoS ONE"},{"issue":"4","key":"1440_CR61","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41418-020-00647-1","volume":"28","author":"SH Lee","year":"2021","unstructured":"Lee SH, Hyeon DY, Yoon S-H, Jeong J-H, Han S-M, Jang J-W, et al. RUNX3 methylation drives hypoxia-induced cell proliferation and antiapoptosis in early tumorigenesis. Cell Death Differ. 2021;28(4):1251\u201369.","journal-title":"Cell Death Differ"},{"issue":"5","key":"1440_CR62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3892\/br.2015.479","volume":"3","author":"S-Y He","year":"2015","unstructured":"He S-Y, Jiang R-F, Jiang J, Xiang Y-S, Wang L. Investigation of methylation and protein expression of the Runx3 gene in colon carcinogenesis. Biomed Rep. 2015;3(5):687\u201390.","journal-title":"Biomed Rep"},{"issue":"2","key":"1440_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-203259","volume":"32","author":"B Kang","year":"2021","unstructured":"Kang B, Lee HS, Jeon SW, Park SY, Choi GS, Lee WK, et al. Progressive alteration of DNA methylation of Alu, MGMT, MINT2, and TFPI2 genes in colonic mucosa during colorectal cancer development. Cancer Biomark. 2021;32(2):231\u20136.","journal-title":"Cancer Biomark"},{"issue":"1","key":"1440_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmoldx.2016.09.009","volume":"19","author":"L Sorber","year":"2017","unstructured":"Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, et al. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn. 2017;19(1):162\u20138.","journal-title":"J Mol Diagn"},{"key":"1440_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5585148","volume":"2021","author":"M Nesic","year":"2021","unstructured":"Nesic M, B\u00f8dker JS, Terp SK, Dybk\u00e6r K. Optimization of preanalytical variables for cfDNA processing and detection of ctDNA in archival plasma samples. Biomed Res Int. 2021;2021:1\u20139.","journal-title":"Biomed Res Int."},{"issue":"1","key":"1440_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1373\/clinchem.2019.306837","volume":"66","author":"R Lampignano","year":"2020","unstructured":"Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, et al. Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (Pre)analytical work flows. Clin Chem. 2020;66(1):149\u201360.","journal-title":"Clin Chem"},{"issue":"7","key":"1440_CR67","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/clinchem\/hvaa103","volume":"66","author":"F Pittella-Silva","year":"2020","unstructured":"Pittella-Silva F, Chin YM, Chan HT, Nagayama S, Miyauchi E, Low SK, et al. Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin Chem. 2020;66(7):946\u201357.","journal-title":"Clin Chem"},{"issue":"4","key":"1440_CR68","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/cclm-2019-0896","volume":"58","author":"JS Lee","year":"2020","unstructured":"Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med. 2020;58(4):527\u201332.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"1440_CR69","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1080\/15592294.2017.1334024","volume":"12","author":"MW \u00d8rntoft","year":"2017","unstructured":"Worm \u00d8rntoft MB, Jensen S\u00d8, Hansen TB, Bramsen JB, Andersen CL. Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA. Epigenetics. 2017;12(8):626\u201336.","journal-title":"Epigenetics"},{"issue":"12_Supplement","key":"1440_CR70","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1158\/1538-7445.AM2022-3391","volume":"82","author":"S\u00d8 Jensen","year":"2022","unstructured":"Jensen S\u00d8, \u00d8gaard N, \u00d8rntoft MW, Rasmussen MH, Bramsen JB, Therkildsen C, et al. Abstract 3391: Methylation analysis using TriMeth indicate that asymptomatic colorectal cancers (CRCs) release less circulating tumor DNA (ctDNA) compared to symptomatic cancers. Cancer Res. 2022;82(12_Supplement):3391.","journal-title":"Cancer Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01440-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T05:04:31Z","timestamp":1676351071000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01440-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01440-w","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}